Veno-Arterial Extracorporeal Life Support in Heart Transplant and Ventricle Assist Device Centres. Meta-analysis.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
04 2021
Historique:
revised: 29 09 2020
received: 10 07 2020
accepted: 19 10 2020
pubmed: 19 12 2020
medline: 2 7 2021
entrez: 18 12 2020
Statut: ppublish

Résumé

Because reported mortality on veno-arterial (V-A) extracorporeal life support (ECLS) substantially varies between centres, the aim of the current analysis was to assess the outcomes between units performing heart transplantation and/or implanting ventricular assist device (HTx/VAD) vs. non-HTx/VAD units in patients undergoing V-A ECLS for cardiogenic shock. Systematic search according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses was performed using PubMed/MEDLINE databases until 30 November 2019. Articles reporting in-hospital/30-day mortality and centre's HTx/VAD status were included. In-hospital outcomes and long-term survival were analysed in subgroup meta-analysis. A total of 174 studies enrolling n = 13 308 patients were included with 20 series performed in non-HTx/VAD centres (1016 patients, 7.8%). Majority of patients underwent V-A ECLS for post-cardiotomy shock (44.2%) and acute myocardial infarction (20.7%). Estimated overall in-hospital mortality was 57.2% (54.9-59.4%). Mortality rates were higher in non-HTx/VAD [65.5% (59.8-70.8%)] as compared with HTx/VAD centres [55.8% (53.3-58.2%)], P < 0.001. Estimated late survival was 61.8% (55.7-67.9%) without differences between non-HTx/VAD and HTx/VAD centres: 66.5% (30.3-1.02%) vs. 61.7% (55.5-67.8%), respectively (P = 0.797). No differences were seen with respect to ECLS duration, limb complications, and reoperations for bleeding, kidney injury, and sepsis. Yet, weaning rates were higher in HTx/VAD vs. non-HTx/VAD centres: 58.7% (56.2-61.1%) vs. 48.9% (42.0-55.9%), P = 0.010. Estimated rate of bridge to heart transplant was 6.6% (5.2-8.3%) with numerical, yet not statistically significant, difference between non-HTx/VAD [2.7% (0.8-8.3%)] as compared with HTx/VAD [6.7% (5.3-8.6%)] (P = 0.131). Survival after V-A ECLS differed according to centre's HTx/VAD status. Potentially different risk profiles of patients must be taken account for before definite conclusions are drawn.

Identifiants

pubmed: 33337072
doi: 10.1002/ehf2.13080
pmc: PMC8006654
doi:

Types de publication

Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Pagination

1064-1075

Informations de copyright

© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

Références

BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
J Am Coll Cardiol. 2014 Oct 7;64(14):1407-15
pubmed: 25277608
Eur Heart J. 2014 Jan;35(3):156-67
pubmed: 24014384
Ann Thorac Surg. 2019 Jan;107(1):311-321
pubmed: 29959943
BMC Med Res Methodol. 2014 Dec 19;14:135
pubmed: 25524443
BMC Cardiovasc Disord. 2020 Jan 9;20(1):10
pubmed: 31918663
J Thorac Cardiovasc Surg. 2017 Jan;153(1):95-101
pubmed: 27666787
Ann Thorac Surg. 2017 Jul;104(1):62-69
pubmed: 28131429
Semin Thorac Cardiovasc Surg. 2015 Summer;27(2):81-8
pubmed: 26686427
Stat Med. 2000 Mar 15;19(5):723-41
pubmed: 10700742
J Heart Lung Transplant. 2019 Nov;38(11):1125-1143
pubmed: 31522913
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880
Eur J Heart Fail. 2015 May;17(5):501-9
pubmed: 25820680
BMC Med Res Methodol. 2012 Feb 01;12:9
pubmed: 22297116
Perfusion. 2020 Apr;35(3):246-254
pubmed: 31469037
Ann Cardiothorac Surg. 2019 Jan;8(1):116-122
pubmed: 30854320
Intensive Care Med. 2016 May;42(5):889-896
pubmed: 26942446
Circulation. 2015 Feb 17;131(7):676-80
pubmed: 25691703
J Am Coll Cardiol. 2019 Feb 19;73(6):654-662
pubmed: 30765031
ESC Heart Fail. 2021 Apr;8(2):1064-1075
pubmed: 33337072
Eur J Cardiothorac Surg. 2019 Apr 1;55(4):773-779
pubmed: 30445489
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
J Thorac Cardiovasc Surg. 2014 Aug;148(2):416-21.e1
pubmed: 24183903
Am J Respir Crit Care Med. 2015 Apr 15;191(8):894-901
pubmed: 25695688

Auteurs

Mariusz Kowalewski (M)

Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior, Centre of Postgraduate Medical Education, Wołoska 137 Str, Warsaw, 02-507, Poland.
Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.
Thoracic Research Centre, Collegium Medicum, Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland.

Kamil Zieliński (K)

Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.

Mirosław Gozdek (M)

Thoracic Research Centre, Collegium Medicum, Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland.
Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.

Giuseppe Maria Raffa (GM)

Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, ISMETT-IRCCS, Palermo, Italy.

Michele Pilato (M)

Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, ISMETT-IRCCS, Palermo, Italy.

Musab Alanazi (M)

Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.

Martijn Gilbers (M)

Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.

Sam Heuts (S)

Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.

Ehsan Natour (E)

Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.

Elham Bidar (E)

Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.

Rick Schreurs (R)

Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.

Thijs Delnoij (T)

Cardiology Department, Maastricht University Medical Centre, Maastricht, The Netherlands.
Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.

Rob Driessen (R)

Cardiology Department, Maastricht University Medical Centre, Maastricht, The Netherlands.
Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.

Jan Willem Sels (JW)

Cardiology Department, Maastricht University Medical Centre, Maastricht, The Netherlands.
Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.

Marcel van de Poll (M)

Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.

Paul Roekaerts (P)

Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.

Michał Pasierski (M)

Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior, Centre of Postgraduate Medical Education, Wołoska 137 Str, Warsaw, 02-507, Poland.

Paolo Meani (P)

Cardiology Department, Maastricht University Medical Centre, Maastricht, The Netherlands.
Department of Intensive Care, Maastricht University Medical Centre, Maastricht, The Netherlands.

Jos Maessen (J)

Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.

Piotr Suwalski (P)

Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior, Centre of Postgraduate Medical Education, Wołoska 137 Str, Warsaw, 02-507, Poland.

Roberto Lorusso (R)

Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands.
Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht, Maastricht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH